Evidence map›Paper›PMID 32613745›Full record

Observational studyESC heart failure2020

Characteristics and 2-year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA-AF.

Sergio J Dubner, Christine Teutsch, Menno V Huisman, Hans-Christoph Diener, Jonathan Halperin, Kenneth J Rothman, Chang-Sheng Ma, Eduardo Chuquiure-Valenzuela, Jutta Bergler-Klein, Kristina Zint and 4 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Observational
  7. Observational
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 13 institutions in 12 countries.

Sergio J DubnerClínica y Maternidad Suizo Argentina, Buenos Aires, Argentina.
Christine TeutschBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Menno V HuismanLeiden University Medical Center, Leiden, the Netherlands.
Hans-Christoph DienerUniversity Hospital Essen, Essen, Germany.
Jonathan HalperinIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Kenneth J RothmanRTI Health Solutions, Research Triangle Institute, Research Triangle Park, NC, USA.
Chang-Sheng MaAtrial Fibrillation Center, Beijing Anzhen Hospital, Beijing, People's Republic of China.
Eduardo Chuquiure-ValenzuelaHeart Failure Center, National Institute of Cardiology, Tlalpan, Mexico.
Jutta Bergler-KleinDepartment of Cardiology, University Clinic of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Kristina ZintBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Lionel Riou FrançaBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Shihai LuBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Miney PaquetteBoehringer Ingelheim, Burlington, ON, Canada.
Gregory Y H LipLiverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.
Boehringer Ingelheim (China) · CNAalborg University · DKBeijing Anzhen Hospital · CNBoehringer Ingelheim (Canada) · CABoehringer Ingelheim (France) · FRBoehringer Ingelheim (Germany) · DEEssen University Hospital · DEIcahn School of Medicine at Mount Sinai · USInstitute of Cardiology · RUInstituto de Efectividad Clínica y Sanitaria · ARLeiden University Medical Center · NLMedical University of Vienna · ATRTI International · US

Funding

Boehringer Ingelheim N/a
6 · The paper itself

Abstract

aimsThis study aimed to describe baseline characteristics of patients with atrial fibrillation (AF) at risk of stroke with and without history of heart failure (HF) and report 2-year outcomes in the dabigatran-treated subset of a prospective, global, observational study (GLORIA-AF). METHODS AND

resultsNewly diagnosed patients with AF and CHA

conclusionsPatients with AF and history of HF may have greater disease burden at AF diagnosis and increased mortality rates vs. patients without HF. Stroke and major bleeding rates were roughly comparable between groups confirming the long-term safety and effectiveness of dabigatran in patients with HF.

Indexed as

Atrial FibrillationHeart FailureStrokeDabigatranHumansProspective StudiesDabigatranAnticoagulationAtrial fibrillationDabigatranHeart failureMajor bleedStroke

Identifiers

PMID32613745
PMCPMC7524082
OpenAlexW3039577959

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.